Proteo, Inc. (PTEO) financial statements (2021 and earlier)
Company profile
| Business Address |
2102 BUSINESS CENTER DRIVE IRVINE, CA 92612 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 89 | 114 | 142 | 237 | 782 | 456 | |||
| Cash and cash equivalents | 89 | 114 | 142 | 237 | 782 | 456 | |||
| Receivables | 38 | 17 | 84 | 71 | |||||
| Other undisclosed current assets | 122 | 132 | 118 | 257 | 314 | 414 | |||
| Total current assets: | 249 | 263 | 343 | 566 | 1,096 | 870 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 5 | 7 | 6 | 9 | 14 | 21 | |||
| Intangible assets, net (including goodwill) | 8 | ✕ | |||||||
| Intangible assets, net (excluding goodwill) | 8 | ||||||||
| Total noncurrent assets: | 5 | 7 | 6 | 9 | 22 | 21 | |||
| TOTAL ASSETS: | 254 | 270 | 349 | 575 | 1,118 | 890 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 127 | 223 | 304 | 97 | 151 | ||||
| Other undisclosed accounts payable and accrued liabilities | 127 | 223 | 304 | 97 | 151 | ||||
| Deferred revenue and credits | ✕ | ✕ | 83 | 212 | |||||
| Other undisclosed current liabilities | 353 | ||||||||
| Total current liabilities: | 127 | 305 | 353 | 517 | 97 | 151 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 798 | 831 | 712 | 713 | 1,260 | ||||
| Deferred revenue and credits | ✕ | ✕ | 567 | ||||||
| Accounts payable and accrued liabilities | 652 | 683 | 600 | 622 | 693 | ||||
| Other liabilities | 145 | 148 | 112 | 92 | |||||
| Other undisclosed noncurrent liabilities | 353 | 785 | |||||||
| Total noncurrent liabilities: | 798 | 831 | 1,064 | 713 | 1,260 | 785 | |||
| Total liabilities: | 925 | 1,136 | 1,417 | 1,230 | 1,357 | 936 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (674) | (866) | (715) | (656) | (239) | (46) | |||
| Preferred stock | 1 | 1 | 1 | ||||||
| Common stock | 24 | 24 | 24 | 24 | 24 | 24 | |||
| Additional paid in capital | 9,144 | 8,988 | 8,988 | 8,988 | 8,988 | 8,988 | |||
| Accumulated other comprehensive income (loss) | (31) | 74 | (24) | 1 | 106 | 251 | |||
| Accumulated deficit | (9,813) | (9,953) | (9,703) | (9,670) | (9,358) | ||||
| Other undisclosed stockholders' equity attributable to parent | 1 | 1 | 1 | (9,309) | |||||
| Stockholders' equity attributable to noncontrolling interest | 3 | ||||||||
| Total stockholders' equity: | (671) | (866) | (715) | (656) | (239) | (46) | |||
| Other undisclosed liabilities and equity | (353) | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 254 | 270 | 349 | 575 | 1,118 | 890 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 206 | 199 | 243 | 826 | 545 | |||
| Revenue, net | ✕ | ✕ | 1,300 | 545 | ||||
| Cost of revenue | (0) | (12) | ||||||
| Gross profit: | 206 | 199 | 243 | 826 | 545 | (12) | ||
| Operating expenses | (209) | (270) | (340) | (1,300) | (763) | (480) | ||
| Operating loss: | (3) | (71) | (98) | (474) | (218) | (492) | ||
| Nonoperating income (expense) | 42 | (178) | 64 | 162 | 328 | (1) | ||
| Foreign currency transaction gain, before tax | 159 | 59 | ||||||
| Other nonoperating income (expense) | 42 | (178) | 64 | 162 | 169 | (60) | ||
| Income (loss) before gain (loss) on sale of properties: | 39 | (249) | (34) | (312) | 110 | (493) | ||
| Other undisclosed net loss | (59) | |||||||
| Net income (loss): | 39 | (249) | (34) | (312) | 110 | (552) | ||
| Net income attributable to noncontrolling interest | 3 | |||||||
| Other undisclosed net loss attributable to parent | (6) | (159) | ||||||
| Net income (loss) available to common stockholders, diluted: | 36 | (249) | (34) | (312) | (49) | (552) | ||
Comprehensive Income ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 39 | (249) | (34) | (312) | 110 | (552) | ||
| Other comprehensive income (loss) | (18) | 3 | 71 | 14 | ||||
| Comprehensive income (loss): | 39 | (268) | (31) | (241) | 125 | (552) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 3 | |||||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (8) | 117 | (28) | (175) | (318) | 64 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 35 | (151) | (59) | (416) | (194) | (488) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.